

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	10/623,189
Confirmation Number	
Filing Date	July 18, 2003
First Named Inventor	DePaoli, Alex M. <i>et al.</i>
Group Art Unit	
Examiner Name	
Attorney Docket No.	54113.8005.US02

Sheet

1

of

7

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			
EOH	A1	5,521,283				
	A2	5,525,705				
	A3	5,532,336				
	A4	5,552,522				
	A5	5,552,523				
	A6	5,552,524				
	A7	5,554,727				
	A8	5,559,208				
	A9	5,563,243				
	A10	5,563,244				
	A11	5,563,245				
	A12	5,567,678				
	A13	5,567,803				
	A14	5,569,743				
	A15	5,569,744				
	A16	5,574,133				
	A17	5,580,954				
	A18	5,594,101				
	A19	5,594,104				
	A20	5,605,886				
	A21	5,614,379				
	A22	5,691,309				
↓	A23	5,719,266				

EXAMINER

/Eileen O'Hara/

DATE CONSIDERED

06/28/2006

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

[54113-8005-US0200/LA033020.040]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number 10/623,189 Confirmation Number Filing Date July 18, 2003 First Named Inventor DePaoli, Alex M. et al. Group Art Unit Examiner Name Attorney Docket No. 54113.8005.US02	
Sheet	2	of	7		

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
EOH	B1		EP 725078					
X	B2		EP 725079					
X	B3		EP 736599					
X	B4		EP 741187					
X	B5		EP 744408					
X	B6		EP 745610					
X	B7		EP 835879					
X	B8		WO 96/05309					
X	B9		WO 96/22308					
X	B10		WO 96/23513					
X	B11		WO 96/23514					
X	B12		WO 96/23515					
X	B13		WO 96/23516					
X	B14		WO 96/23517					
X	B15		WO 96/23518					
X	B16		WO 96/23519					
X	B17		WO 96/27385					
X	B18		WO 96/31526					
X	B19		WO 96/34111					
X	B20		WO 96/34885					
X	B21		WO 96/35787					
X	B22		WO 96/37517					
X	B23		WO 96/40912					
X	B24		WO 97/00886					
X	B25		WO 97/06816					
X	B26		WO 97/16550					
X	B27		WO 97/18833					

EXAMINER
 /Eileen O'Hara/
 /Eileen O'Hara/

DATE CONSIDERED
 /Eileen O'Hara/

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/623,189
				Confirmation Number	
				Filing Date	July 18, 2003
				First Named Inventor	DePaoli, Alex M. <i>et al.</i>
				Group Art Unit	
Examiner Name					
Attorney Docket No.	54113.8005.US02				


FOREIGN PATENT DOCUMENTS						
		Foreign Patent or Application				
EOH	B28		WO 97/20933			
↓	* B29		WO 97/38014			
	* B30		WO 97/46585			
	* B31		WO 98/08512			
	* B32		WO 98/28427			
↓	* B33		WO 00/20872			

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
EOH	C1	ABATE, N., <i>et al.</i> , "Estimation of Adipose Tissue Mass By Magnetic Resonance Imaging: Validation Against Dissection in Human Cadavers," <i>J. Lipid Res.</i> 1994; 35:1490-6.	
	C2	AHIMA, R.S., <i>et al.</i> , "Role of Leptin in the Neuroendocrine Response to Fasting," <i>Nature</i> 1996: 382:250-2.	
	C3	ARIOGLU, E., <i>et al.</i> , "Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes," <i>An Intern Med.</i> 2000; 133:263-74.	
	C4	BERASAIN, C., <i>et al.</i> , "Pathological and Virological Findings in Patients With Persistent Hypertransaminasaemia of Unknown Etiology," <i>Gut.</i> 2000:47:429-35.	
	C5	BERG, A.H., <i>et al.</i> , "The Adipocyte-Secreted Protein Acrp30 Enhances Hepatic Insulin Action," <i>Nat Med.</i> 2001; 7:947-53.	
	C6	BOLAN, C., <i>et al.</i> , "Intensive, Long-Term Plasma Exchange Therapy For Severe Hypertriglyceridemia in Acquired Generalized Lipoatrophy," <i>J. Clin Endocrin And Metab</i> (Submitted).	
	C7	BURANT, C.F., <i>et al.</i> , "Troglitazone Action Is Independent of Adipose Tissue," <i>J. Clin Invest.</i> 1997; 100:2900-8.	
↓	C8	CAMPFIELD, L.A., <i>et al.</i> , "Recombinant Mouse OB Protein: Evidence For A Peripheral Signal Linking Adiposity and Central Neural Networks," <i>Science</i> 1995: 269:546-9.	

EXAMINER	/Eileen O'Hara/ /Eileen O'Hara/	DATE CONSIDERED	06/28/2006
----------	------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)		COMPLETE IF KNOWN	
		Application Number	10/623,189
		Confirmation Number	
		Filing Date	July 18, 2003
		First Named Inventor	DePaoli, Alex M. <i>et al.</i>
		Group Art Unit	
		Examiner Name	
Sheet	4	of	54113.8005.US02



OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
EOH	C9	CAO, H., <i>et al.</i> , "Nuclear Lamin A/C R482q Mutation in Canadian Kindreds With Dunnigan-Type Familial Partial Lipodystrophy," <i>Hum Mol Genet.</i> 2000; 9:109-12.	
	C10	COSIDINE, R.V., <i>et al.</i> , "Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans," <i>N Engl J Med.</i> 1996; 334:292-5.	
	C11	EBIHARA, K., <i>et al.</i> , "Transgenic Overexpression of Leptin Rescues Insulin Resistance and Diabetes in A Mouse Model of Lipoatrophic Diabetes," <i>Diabetes</i> 2001; 50:1440-8.	
	C12	FAROOQI, I.S., <i>et al.</i> , "Effects of Recombinant Leptin Therapy in A Child With Congenital Leptin Deficiency," <i>N Engl J Med.</i> 1999; 341:879-84.	
	C13	FESKANICH, D., <i>et al.</i> , "Reproducibility and Validity of Food Intake Measurements From A Semiquantitative Food Frequency Questionnaire," <i>J Am Diet Assoc.</i> 1993; 93:790-6.	
	C14	FRUEBIS, J., <i>et al.</i> , "Proteolytic Cleavage Product of 30-Kda Adipocyte Complement-Related Protein Increases Fatty Acid Oxidation in Muscle and Causes Weight Loss in Mice," <i>Proc Natl Acad Sci U S A</i> 2001; 98:2005-L0.	
	C15	GARG, A., <i>et al.</i> , "Adipose Tissue Distribution Pattern in Patients With Familial Partial Lipodystrophy (Dunnigan Variety)," <i>J Clin Endocrinol Metab</i> 1999; 84:170-4.	
	C16	GARG, A., <i>et al.</i> , "Peculiar Distribution of Adipose Tissue in Patients With Congenital Generalized Lipodystrophy," <i>J Clin Endocrinol Metab.</i> 1992; 75:358-61.	
	C17	GARG, A., <i>et al.</i> , "Lipodystrophies," <i>Am J Med.</i> 2000; 108:143-52.	
	C18	GAVRILOVA, O., <i>et al.</i> , "Surgical Implantation of Adipose Tissue Reverses Diabetes in Lipoatrophic Mice," <i>J Clin Invest</i> 2000; 105: 271-8.	
↓	C19	GOTTO, A.M., Jr., "Triglyceride As A Risk Factor For Coronary Artery Disease," <i>Am J Cardiol</i> 1998; 82: 22Q25Q.	

EXAMINER	/Eileen O'Hara/ /Eileen O'Hara/	DATE CONSIDERED	/Eileen O'Hara/
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN		
			Application Number	10/623,189	
			Confirmation Number		
			Filing Date	July 18, 2003	
			First Named Inventor	DePaoli, Alex M. <i>et al.</i>	
			Group Art Unit		
Sheet	5	of		Examiner Name	
				Attorney Docket No.	54113.8005.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
EOH	C20	HALAAS, J.L., <i>et al.</i> , "Weight-Reducing Effects of the Plasma Protein Encoded By the Obese Gene," <i>Science</i> 1995; 269:543-6.		
	C21	HARRISION, L.C., <i>et al.</i> , "Correlation Between Insulin Receptor Binding in Isolated Fat Cells and Insulin Sensitivity in Obese Human Subjects," <i>J Clin Invest</i> 1976; 58:1435-41.		
	C22	HEYMSFIELD, S.B., <i>et al.</i> , "Recombinant Leptin For Weight Loss in Obese and Lean Adults: A Randomized, Controlled, Dose-Escalation Trial [See Comments]," <i>Jama</i> 1999; 282:1568-75.		
	C23	"Intensive Blood-Glucose Control With Sulphonylureas Or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33)," <i>UK Prospective Diabetes Study (UKPDS) Group, Lancet</i> 1998; 352:837-53.		
	C24	KREISBERG, R.A., "Diabetic Dyslipidemia," <i>Am J Cardiol</i> 1998; 82:67U-73U		
	C25	LAMBRINOUDAKI, I., <i>et al.</i> , "Body Composition Assessment By Dual-Energy X-Ray Absorptionmetry: Comparison of Prone and Supine Measurements," <i>Metabolism</i> 1998; 47:1379-82.		
	C26	LAWRENCE, R.D., "Lipodystrophy and Hepatomegaly With Diabetes, Lipaemia, and Other Metabolic Disturbances: A Case Throwing New Light On the Action of Insulin," <i>Lancet</i> 1946; 1:724-731 and 773-775.		
	C27	LUYCKX, F.H., <i>et al.</i> , "Non-Alcoholic Steatohepatitis: Association With Obesity and Insulin Resistance, and Influence of Weight Loss," <i>Diabetes Metab</i> 2000; 26:98-106.		
	C28	MAGRE, J., <i>et al.</i> , "Identification of the Gene Altered in Berardinelli-Seip Congenital Lipodystrophy On Chromosome 11q13," <i>Nat Genet</i> 2001; 28:365-70.		
↓	C29	MANTON, N.D., <i>et al.</i> , "Non-Alcoholic Steatohepatitis in Children and Adolescents," <i>Med J Aust</i> 2000; 173:476-9.		

EXAMINER	/Eileen O'Hara/ /Eileen O'Hara/	DATE CONSIDERED	06/28/2006
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN		
			Application Number	10/623,189	
			Confirmation Number		
			Filing Date	July 18, 2003	
			First Named Inventor	DePaoli, Alex M. <i>et al.</i>	
			Group Art Unit		
Examiner Name					
Sheet	6	of		Attorney Docket No.	54113.8005.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
EOH	C30	MANTZOROS, C.S., <i>et al.</i> , "Editorial: Leptin As A Therapeutic Agent-Trials and Tribulations," <i>J Clin Endocrinol Metab</i> 2000; 85:4000-2.		
	C31	MOITRA, J., <i>et al.</i> , "Life Without White Fat: A Transgenic Mouse," <i>Genes Dev</i> 1998; 12: 3168-81.		
	C32	MONTAGUE, C.T., <i>et al.</i> , "Congenital Leptin Deficiency Is Associated With Severe Early Onset Obesity in Humans," <i>Nature</i> 1997; 387:903-8.		
	C33	PELLEYMOUNTER, M.A., <i>et al.</i> , "Effects of the Obese Gene Product On Body Weight Regulation in ob/ob Mice," <i>Science</i> 1995; 269:540-3.		
	C34	PETERS, A.L., <i>et al.</i> , "The New Diagnostic Criteria For Diabetes: The Impact on Management of Diabetes and Macrovascular Risk Factors," <i>Am J Med</i> 1998; 105:15s-19s.		
	C35	REITMAN, M.L., <i>et al.</i> , "Lipoatrophy Revisited," <i>Trends Endocrinol Metab.</i> 2000; 11:410-6.		
	C36	SHIMOMURA, I., <i>et al.</i> , "Decreased IRS-2 and Increased SREBP-1c Lead To Mixed Insulin Resistance and Sensitivity in Livers of Lipodystrophic and ob/ob Mice," <i>Mol Cel</i> 2000; 6:77-86.		
	C37	SHIMOMURA, I., <i>et al.</i> , "Insulin Resistance and Diabetes Mellitus in Transgenic Mice Expressing Nuclear SREBP-1c in Adipose Tissue: Model For Congenital Generalized Lipodystrophy," <i>Genes Dev</i> 1998; 12:3182-94.		
	C38	SHIMOMURA, I., <i>et al.</i> , "Leptin Reverses Insulin Resistance and Diabetes Mellitus in Mice With Congenital Lipodystrophy," <i>Nature</i> 1999; 401:73-6.		
	C39	TRYGSTAD, O., <i>et al.</i> , "Lipodystrophic Diabetes Treated With Fenfluramine," <i>Int J Obes</i> 1977; 1:287-92.		
↓	C40	UNGER, R.H., <i>et al.</i> , "Regulation of Fatty Acid Homeostasis in Cells: Novel Role of Leptin," <i>Proc Natl Acad Sci U S A</i> 1999; 96:2327-32.		

EXAMINER	DATE CONSIDERED
/Eileen O'Hara/ Eileen O'Hara/	06/28/2006
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN	
			Application Number	10/623,189
			Confirmation Number	
			Filing Date	July 18, 2003
			First Named Inventor	DePaoli, Alex M. <i>et al.</i>
			Group Art Unit	
Examiner Name				
Attorney Docket No.	54113.8005.US02			
Sheet	7	of		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
EOH	C41	UNGER, R.H., <i>et al.</i> , "Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM, Genetic and Clinical Implications," <i>Diabetes</i> 1995; 44:863-70.		
	C42	YAMAUCHI, T., <i>et al.</i> , "The Fat-Derived Hormone Adiponectin Reverses Insulin Resistance Associated with Both Lipoatrophy and Obesity," <i>Nat Med.</i> 2001; 7:941-6.		
	C43	ZHANG, Y., <i>et al.</i> , "Positional Cloning of the Mouse Obese Gene and Its Human Homologue," <i>Nature</i> 1994; 372:425-32.		
↓	C44	ZHANG, Y., <i>et al.</i> , Correction at <i>Nature</i> , 374:479 (1995).		

EXAMINER	/Eileen O'Hara/ /Eileen O'Hara/	DATE CONSIDERED	06/28/2006
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/623,189
				Confirmation Number	
				Filing Date	July 18, 2003
				First Named Inventor	DePaoli, Alex M. <i>et al.</i>
				Group Art Unit	
Examiner Name					
Attorney Docket No.	54113.8005.US02				


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			
EOH	A24	6,258,932		Vahine, <i>et al.</i>		

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
EOH	C45	BERG, Jens P., "Leptin is a potent Anti-diabetic in Mice with Lipodystrophy and Insulin Resistance," <i>European Journal of Endocrinology</i> 2000; 142:114-116.	
EOH	C46	HADIGAN, Colleen, <i>et al.</i> , "Metformin in the Treatment of HIV Lipodystrophy Syndrome," <i>Journal of the American Medical Association</i> July 26, 2000; 284:4:472-477.	

EXAMINER	/Eileen O'Hara/	DATE CONSIDERED	06/28/2006
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

JFW

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10623189	
	Filing Date		2003-07-18	
	First Named Inventor	Alex M. DEPAOLI		
	Art Unit	1646		
	Examiner Name	Eileen O'Hara		
	Attorney Docket Number	54113.8005.US02		

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>


If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10623189
Filing Date	2003-07-18
First Named Inventor	Alex M. DEPAOL
Art Unit	1646
Examiner Name	Eileen O'Hara
Attorney Docket Number	54113.8005.US02



EOH	1	BERG, J.P., "Leptin is a potent anti-diabetic in mice with lipodystrophy and insulin resistance," European Journal of Endocrinology, Scandinavian University Press, Vol. 142, 2000, pp. 114-116.	<input type="checkbox"/>
EOH	2	EUROPEAN PATENT OFFICE, Supplementary European Search Report for EP 02793811, 2006/03/20.	<input type="checkbox"/>
EOH	3	JAUQUET, D. et al., "Extremely low values of serum leptin in children with congenital generalized lipoatrophy," European Journal of Endocrinology, Vol. 140, no. 1, Jan. 1999, pp. 107-109.	<input type="checkbox"/>
EOH	4	OGAWA, Yoshihiro et al., "Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin," Diabetes, Vol. 48, no. 9, Sep. 1999, pp. 1822-1829.	<input type="checkbox"/>
EOH	5	VAN DER MERWE, M. T. et al, "Free fatty acids and insulin levels: Relationship to leptin levels and body composition in various patient groups from South Africa," International Journal of Obesity, vol. 23, no. 9, Sep 1999, pp. 909-917.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Eileen O'Hara/	Date Considered	07/03/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.